Supplementary Oxygen in Surgical and Medical Wards Evaluated by 30-day Mortality

Hannibal Troensegaard11,196 enrolled

Overview

This study evaluates the use and effects of supplementary oxygen in surgical and medical wards on patients admitted to a hospital in the capital region of Denmark. The population will be divided in to three groups according to their oxygenation status. The main outcome will be 30-day mortality, with secondary outcomes being Length of stay, 30-day admission to ICU, 30-day reoperations, 30-day readmission, and peak values within 30-days of C-reactive protein, S-Creatinine, Troponin.

Study Type

OBSERVATIONAL

Enrollment

11,196

Conditions

Oxygen Toxicity Oxygen Deficiency

Interventions

Oxygen gasDRUG

Supplementary oxygen supplied via nasal catheter or oxygen mask during hospital admission.

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Admission date between 1st of January 2014 to 29th of December 2014 on a hospital in the capital region of Denmark * Age ≥18 * Unique (first) admission in database for either: * Hip fracture requiring surgery * Chronic obstructive pulmonary disease in exacerbation * Acute mycardial infarction * Open abdominal surgery Exclusion Criteria: * No data on saturation within 48 hours after * Admission (Medical patients) * Discharge from the post anaesthesia care unit (Surgical patients) * No data on primary outcome (30-day mortality)

Locations (1)

Bispebjerg og Frederiksberg Hospital

Copenhagen, NV, Denmark

Outcomes

Primary Outcomes

30- day mortality

Will be reported as a fraction of positives within the exposure group population

Time frame: 30 days

Secondary Outcomes

Length of stay

Length of hospital stay in days

Time frame: 30 days

Organ markers in blood samples

Highest value of C-reactive protein, Troponin and Creatinine within 30 days.

Time frame: 30 days

30- day admission to ICU

Will be reported as a fraction of positives within the exposure group population.

Time frame: 30 days

30- day readmission

will be reported as a fraction of positives within the exposure group population.

Time frame: 30 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.